Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
The Phase II EZH2 Inhibitor Trial
Frontiers | Easy or Not—The Advances of EZH2 in Regulating T Cell Development, Differentiation, and Activation in Antitumor Immunity
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation - ScienceDirect
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial - The Lancet Haematology
SAM-competitive EZH2 inhibitors in clinical trials | Download Scientific Diagram
Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis | Cell Death Discovery
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition: Trends in Immunology
EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma | PLOS ONE
Current clinical trials for EZH2 inhibitors. | Download Table
Pre-clinical studies of EZH2 inhibitors in MM | Download Table
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype | Clinical Epigenetics | Full Text
Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation | Nature Communications
Frontiers | EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment
Clinical studies involving EZH2 inhibitors in haematological neoplasms | Download Table
Known EZH2 inhibitors. GSK126, tazemetostat and CPI-1205 are in... | Download Scientific Diagram
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies | Biomarker Research | Full Text
EZH2: a novel target for cancer treatment | Journal of Hematology & Oncology | Full Text
Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction | Journal of Medicinal Chemistry
